Efavirenz and Ubrogepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A4 induction may reduce ubrogepant exposure.
Clinical significance and safety
Efavirenz can reduce ubrogepant exposure by inducing CYP3A4. A modified ubrogepant regimen is recommended with moderate or weak inducers, although these combinations were not individually studied in the US label. A clinician should check the treatment plan and monitor whether migraine control is reduced.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.